Review : Current and new generation pneumococcal vaccines

Show simple item record Feldman, Charles Anderson, Ronald 2014-11-07T12:06:32Z 2014-11-07T12:06:32Z 2014-10
dc.description.abstract Pneumococcal polysaccharide vaccines (PPVs) and conjugate vaccines (PCVs), of which PPV23 and PCV13 are the current front runners, have had a significant, beneficial impact on public health. With regard to PPV23, there has been some debate, however, about its protective efficacy against all-cause pneumonia, as opposed to invasive pneumococcal disease, in high-risk cases. PCVs, on the other hand, have been included in many national immunisation programmes for prevention of severe pneumococcal disease in infants and young children, as well as for adults in various high-risk categories. Although innovative and effective, the protective efficacy of PCVs, the composition of which is based on the geographic prevalence and virulence of pneumococcal serotypes, is limited due to colonisation of the nasopharynx with non-vaccine serotypes. This phenomenon of serotype replacement has provided the impetus for development of new generation recombinant protein and whole cell pneumococcal vaccines with the potential to provide serotype-independent protection. In addition to an overview of the successes and limitations of PPVs and PCVs, this review is focused on emerging and pipeline protein-based and whole cell vaccines, preceded by a consideration of conserved pneumococcal virulence factors which are potential vaccine candidates. en_US
dc.description.librarian hj2014 en_US
dc.description.sponsorship National Research Foundation (SA) en_US
dc.description.uri en_US
dc.identifier.citation Feldman, C & Anderson, R 2014, 'Review : Current and new generation pneumococcal vaccines', Journal of Infection, vol. 69, no. 4, pp. 309-325. en_US
dc.identifier.issn 0163-4453 (print)
dc.identifier.issn 1532-2742 (online)
dc.identifier.other 10.1016/j.jinf.2014.06.006
dc.language.iso en en_US
dc.publisher Elsevier en_US
dc.rights © 2014 Published by Elsevier Ltd on behalf of The British Infection Association. Notice : this is the author’s version of a work that was accepted for publication in Journal of Infection. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Journal of Infection, vol. 69, no. 4, pp. 309-325, 2014. doi : 10.1016/j.jinf.2014.06.006. en_US
dc.subject Pneumococcal polysaccharide vaccines (PPVs) en_US
dc.subject Pneumococcal conjugate vaccines (PCVs) en_US
dc.subject Pneumococcal choline binding protein A en_US
dc.subject Pneumococcal surface protein A en_US
dc.subject Pneumococcal surface protein C en_US
dc.subject Pneumolysin en_US
dc.subject Polyhistidine triad proteins en_US
dc.subject Recombinant protein vaccines en_US
dc.subject Streptococcus pneumoniae en_US
dc.subject Whole cell vaccines en_US
dc.title Review : Current and new generation pneumococcal vaccines en_US
dc.type Postprint Article en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record